Catalytic antibodies as magic bullets

Chemistry - A European Journal

Volumn 6, Issue 12, 2000, Pages 2091-2095

  Rader, Christoph ^a   List, Benjamin ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibody catalysis; Bifunctional antibodies; Cancer therapy; Prodrugs; Selective chemotherapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CATALYTIC ANTIBODY; DOXORUBICIN; MONOCLONAL ANTIBODY; PRODRUG; REAGENT; RITUXIMAB; TRASTUZUMAB;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CATALYSIS; CLINICAL TRIAL; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NONHUMAN; TUMOR CELL DESTRUCTION;

ANTIBODIES, CATALYTIC; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0034674313     PISSN: 09476539     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3765(20000616)6:12<2091::AID-CHEM2091>3.0.CO;2-S     Document Type: Article

References (32)

1. G. Köhler, C. Milstein, Nature 1975, 256, 503.
2. P. Carter, A. M. Merchant, Curr. Opin. Biotechnol. 1997, 8, 449.
3. a) A. M. Thayer, Chem. Eng. News 1998, August 10, 19;
4. b) S. Dickman, Science 1998, 280, 1196:
5. c) P. Holliger, H. Hoogenboom, Nat. Biotechnol. 1998, 16, 1015;
6. d) C. Milstein, H. Waldmann. Curr. Opin. Immunol. 1999, 11, 589.
7. "[Der Stoff] würde in diesem Sinne genau den Immunproduk-ten des Organismus entsprechen, die ihrerseits nach Art von Zauberkugeln ihren Feind, die Parasiten, isoliert treffen. [...] Die Tumorzellen sind mithin, im Gegensatz zu dem Parasiten, nichts dem Körper Fremdartiges, sondern es handelt sich gewissermaßen um feindliche Brüder, und es ist deshalb a priori viel schwerer, spezifische Heilstoffe aufzufinden, die nur die kranke Zelle treffen, ohne die gesunde zu schädigen. [...]" Translation: "[The compound] would in this respect match exactly the immuno products of the organism, which themselves would target solely their enemy, that is the parasites, like magic bullets. [...] The tumor cells are. contrary to the parasites, not unfamiliar to the body, but are rather enemy brethren, and it is therefore a priori much more difficult to find specific drugs which would target only the infected cell without affecting the healthy cell. [...]" Paul Ehrlich (1854-1915), Universität Göttingen and Königliches Institut für experimentelle Therapie. Frankfurt am Main. Cf. Chemotherapie (1913) in The Collected Papers of Paul Ehrlich, Vol. III. Pergamon Press, London, 1960, pp. 443-455.
8. a) C. F. Barbas III, Nat. Med. 1995, 1, 837:
9. b) C. Rader, C. F. Barbas III, Curr. Opin. Biotechnol. 1997, 8, 503:
10. c) C. Rader, D. A. Cheresh, C. F. Barbas III, Proc. Natl. Acad. Sci. USA 1998, 95, 8910;
11. d) P. J. Hudson, Curr. Opin. Immunol. 1999, 11, 548.
12. J. G. Jurcic, D. A. Scheinberg, A. N. Houghton, Cancer Chemother. Biol. Response Modif. 1997, 17, 195.
13. a) L. N. Jungheim, T. A. Shepherd, Chem. Rev. 1994, 94, 1553;
14. b) P. D. Senter, H. Svensson, Adv. Drug Delivery Rev. 1996, 22, 341:
15. c) I. Niculescu-Duvaz, C. J. Springer, Adv. Drug Delivery Rev. 1997, 26, 151;
16. d) K. D. Bagshawe, S. K. Sharma, P. J. Burke, R. G. Melton, R. J. Knox, Curr. Opin. Immunol. 1999, 11, 579.
17. Y. Cao, M. R. Suresh, Bioconjugate Chem. 1998, 9, 635.
18. H. Miyashita, Y. Karaki, M. Kikuchi, I. Fujii, Proc. Natl. Acad. Sci. USA 1993, 90, 5337.
19. D. A. Campbell, B. Gong, L. M. Kochersperger, S. Yonkovich, M. A. Gallop, P. G. Schultz, J. Am. Chem. Soc. 1994, 116, 2165.
20. P. Wentworth, A. Datta, D. Blakey, T. Boyle, L. J. Partridge, G. M. Blackburn, Proc. Natl. Acad. Sci. USA 1996, 93, 799.
21. a) J. Wagner, R. A. Lerner, C. F. Barbas III, Science 1995, 270, 1797;
22. b) C. F. Barbas III, A. Heine, G. Zhong, T. Hoffmann, S. Gramatikova, R. Bjoernestedt, B. List, J. Anderson, E. A. Stura, I. A. Wilson, R. A. Lerner, Science 1997, 278, 2085;
23. c) T. Hoffmann, G. Zhong, B. List, D. Shabat, J. Anderson, S. Gramatikova, R. A. Lerner, C. F. Barbas III, J. Am. Chem. Soc. 1998, 120, 2768;
24. d) G. F. Zhong, D. Shabat, B. List, J. Anderson, S. C. Sinha, R. A. Lerner, C. F. Barbas III, Angew. Chem. 1998, 110, 2609; Angew. Chem. Int. Ed. 1998, 37, 2481;
25. d) G. F. Zhong, D. Shabat, B. List, J. Anderson, S. C. Sinha, R. A. Lerner, C. F. Barbas III, Angew. Chem. 1998, 110, 2609; Angew. Chem. Int. Ed. 1998, 37, 2481;
26. e) B. List, D. Shabat, G. F. Zhong, J. M. Turner, T. Li, T. Bui, J. Anderson, R. A. Lerner, C. F. Barbas III, J. Am. Chem. Soc. 1999, 121, 7283.
27. G. F. Zhong, R. A. Lerner, C. F. Barbas III, Angew. Chem. 1999. 111, 3957; Angew. Chem. Int. Ed. 1999, 38, 3738.
28. G. F. Zhong, R. A. Lerner, C. F. Barbas III, Angew. Chem. 1999. 111, 3957; Angew. Chem. Int. Ed. 1999, 38, 3738.
29. D. Shabat, S. C. Sinha, R. A. Lerner, C. F. Barbas III, The Scripps Research Institute, La Jolla, CA, unpublished results.
30. B. List, C. F. Barbas III, R. A. Lerner, Proc. Natl. Acad. Sci. USA 1998, 95, 15351.
31. D. Shabat, C. Rader, B. List, R. A. Lerner, C. F. Barbas III, Proc. Natl. Acad. Sci. USA 1999, 96, 6925.
32. Antibody 38C2 catalyzed retro-aldol reactions are generally highly enantioselective. However, at 37 °C the enantioselectivily is lowered. With substrates 3 and 4 (which are diasteromeric mixtures) this allows for complete conversion.